203 related articles for article (PubMed ID: 22623771)
1. B-lymphocyte dysfunction in chronic HIV-1 infection does not prevent cross-clade neutralization breadth.
Boliar S; Murphy MK; Tran TC; Carnathan DG; Armstrong WS; Silvestri G; Derdeyn CA
J Virol; 2012 Aug; 86(15):8031-40. PubMed ID: 22623771
[TBL] [Abstract][Full Text] [Related]
2. Early preservation of CXCR5+ PD-1+ helper T cells and B cell activation predict the breadth of neutralizing antibody responses in chronic HIV-1 infection.
Cohen K; Altfeld M; Alter G; Stamatatos L
J Virol; 2014 Nov; 88(22):13310-21. PubMed ID: 25210168
[TBL] [Abstract][Full Text] [Related]
3. Profiles of neutralizing antibody response in chronically human immunodeficiency virus type 1 clade B'-infected former plasma donors from China naive to antiretroviral therapy.
Hu X; Hong K; Zhao C; Zheng Y; Ma L; Ruan Y; Gao H; Greene K; Sarzotti-Kelsoe M; Montefiori DC; Shao Y
J Gen Virol; 2012 Oct; 93(Pt 10):2267-2278. PubMed ID: 22791603
[TBL] [Abstract][Full Text] [Related]
4. Increased frequencies of CD8
Palmer CD; Romero-Tejeda M; Scully EP; Lockhart A; Seaman MS; Goldenthal A; Piechocka-Trocha A; Walker BD; Chibnik LB; Jost S; Porichis F
J Int AIDS Soc; 2016; 19(1):21136. PubMed ID: 27938646
[TBL] [Abstract][Full Text] [Related]
5. Signature biochemical properties of broadly cross-reactive HIV-1 neutralizing antibodies in human plasma.
Sajadi MM; Lewis GK; Seaman MS; Guan Y; Redfield RR; DeVico AL
J Virol; 2012 May; 86(9):5014-25. PubMed ID: 22379105
[TBL] [Abstract][Full Text] [Related]
6. B cell depletion in HIV-1 subtype A infected Ugandan adults: relationship to CD4 T cell count, viral load and humoral immune responses.
Oballah P; Flach B; Eller LA; Eller MA; Ouma B; de Souza M; Kibuuka HN; Wabwire-Mangen F; Brown BK; Michael NL; Robb ML; Montefiori D; Polonis VR
PLoS One; 2011; 6(8):e22653. PubMed ID: 21886768
[TBL] [Abstract][Full Text] [Related]
7. B cell responses to HIV antigen are a potent correlate of viremia in HIV-1 infection and improve with PD-1 blockade.
Nicholas KJ; Zern EK; Barnett L; Smith RM; Lorey SL; Copeland CA; Sadagopal S; Kalams SA
PLoS One; 2013; 8(12):e84185. PubMed ID: 24358343
[TBL] [Abstract][Full Text] [Related]
8. Anticardiolipin antibodies in HIV infection are independently associated with antibodies to the membrane proximal external region of gp41 and with cell-associated HIV DNA and immune activation.
Martinez V; Diemert MC; Braibant M; Potard V; Charuel JL; Barin F; Costagliola D; Caumes E; Clauvel JP; Autran B; Musset L;
Clin Infect Dis; 2009 Jan; 48(1):123-32. PubMed ID: 19035778
[TBL] [Abstract][Full Text] [Related]
9. Highly efficient neutralization by plasma antibodies from human immunodeficiency virus type-1 infected individuals on antiretroviral drug therapy.
Andrabi R; Makhdoomi MA; Kumar R; Bala M; Parray H; Gupta A; Kotnala A; Thirumurthy V; Luthra K
J Clin Immunol; 2014 May; 34(4):504-13. PubMed ID: 24682667
[TBL] [Abstract][Full Text] [Related]
10. HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4(+) T cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trial.
Ensoli B; Nchabeleng M; Ensoli F; Tripiciano A; Bellino S; Picconi O; Sgadari C; Longo O; Tavoschi L; Joffe D; Cafaro A; Francavilla V; Moretti S; Pavone Cossut MR; Collacchi B; Arancio A; Paniccia G; Casabianca A; Magnani M; Buttò S; Levendal E; Ndimande JV; Asia B; Pillay Y; Garaci E; Monini P;
Retrovirology; 2016 Jun; 13(1):34. PubMed ID: 27277839
[TBL] [Abstract][Full Text] [Related]
11. Circulating CXCR5
Martin-Gayo E; Cronin J; Hickman T; Ouyang Z; Lindqvist M; Kolb KE; Schulze Zur Wiesch J; Cubas R; Porichis F; Shalek AK; van Lunzen J; Haddad EK; Walker BD; Kaufmann DE; Lichterfeld M; Yu XG
JCI Insight; 2017 Jan; 2(2):e89574. PubMed ID: 28138558
[TBL] [Abstract][Full Text] [Related]
12. Antibody-dependent cellular cytotoxicity against primary HIV-infected CD4+ T cells is directly associated with the magnitude of surface IgG binding.
Smalls-Mantey A; Doria-Rose N; Klein R; Patamawenu A; Migueles SA; Ko SY; Hallahan CW; Wong H; Liu B; You L; Scheid J; Kappes JC; Ochsenbauer C; Nabel GJ; Mascola JR; Connors M
J Virol; 2012 Aug; 86(16):8672-80. PubMed ID: 22674985
[TBL] [Abstract][Full Text] [Related]
13. HIV-Specific B Cell Frequency Correlates with Neutralization Breadth in Patients Naturally Controlling HIV-Infection.
Rouers A; Klingler J; Su B; Samri A; Laumond G; Even S; Avettand-Fenoel V; Richetta C; Paul N; Boufassa F; Hocqueloux L; Mouquet H; Rouzioux C; Lambotte O; Autran B; Graff-Dubois S; Moog C; Moris A;
EBioMedicine; 2017 Jul; 21():158-169. PubMed ID: 28615147
[TBL] [Abstract][Full Text] [Related]
14. CD72/CD100 and PD-1/PD-L1 markers are increased on T and B cells in HIV-1+ viremic individuals, and CD72/CD100 axis is correlated with T-cell exhaustion.
Correa-Rocha R; Lopez-Abente J; Gutierrez C; Pérez-Fernández VA; Prieto-Sánchez A; Moreno-Guillen S; Muñoz-Fernández MÁ; Pion M
PLoS One; 2018; 13(8):e0203419. PubMed ID: 30161254
[TBL] [Abstract][Full Text] [Related]
15. Frequencies of Circulating Th1-Biased T Follicular Helper Cells in Acute HIV-1 Infection Correlate with the Development of HIV-Specific Antibody Responses and Lower Set Point Viral Load.
Baiyegunhi O; Ndlovu B; Ogunshola F; Ismail N; Walker BD; Ndung'u T; Ndhlovu ZM
J Virol; 2018 Aug; 92(15):. PubMed ID: 29793949
[TBL] [Abstract][Full Text] [Related]
16. Broadly cross-neutralizing antibodies in HIV-1 patients with undetectable viremia.
Medina-Ramírez M; Sánchez-Merino V; Sánchez-Palomino S; Merino-Mansilla A; Ferreira CB; Pérez I; González N; Alvarez A; Alcocer-González JM; García F; Gatell JM; Alcamí J; Yuste E
J Virol; 2011 Jun; 85(12):5804-13. PubMed ID: 21471239
[TBL] [Abstract][Full Text] [Related]
17. HIV-specific CD4-induced Antibodies Mediate Broad and Potent Antibody-dependent Cellular Cytotoxicity Activity and Are Commonly Detected in Plasma From HIV-infected humans.
Williams KL; Cortez V; Dingens AS; Gach JS; Rainwater S; Weis JF; Chen X; Spearman P; Forthal DN; Overbaugh J
EBioMedicine; 2015 Oct; 2(10):1464-77. PubMed ID: 26629541
[TBL] [Abstract][Full Text] [Related]
18. Achieving Potent Autologous Neutralizing Antibody Responses against Tier 2 HIV-1 Viruses by Strategic Selection of Envelope Immunogens.
Hessell AJ; Malherbe DC; Pissani F; McBurney S; Krebs SJ; Gomes M; Pandey S; Sutton WF; Burwitz BJ; Gray M; Robins H; Park BS; Sacha JB; LaBranche CC; Fuller DH; Montefiori DC; Stamatatos L; Sather DN; Haigwood NL
J Immunol; 2016 Apr; 196(7):3064-78. PubMed ID: 26944928
[TBL] [Abstract][Full Text] [Related]
19. Down-regulation of CD73 on B cells of patients with viremic HIV correlates with B cell activation and disease progression.
Kim ES; Ackermann C; Tóth I; Dierks P; Eberhard JM; Wroblewski R; Scherg F; Geyer M; Schmidt RE; Beisel C; Bockhorn M; Haag F; van Lunzen J; Schulze Zur Wiesch J
J Leukoc Biol; 2017 May; 101(5):1263-1271. PubMed ID: 28193736
[TBL] [Abstract][Full Text] [Related]
20. Association between different anti-Tat antibody isotypes and HIV disease progression: data from an African cohort.
Nicoli F; Chachage M; Clowes P; Bauer A; Kowour D; Ensoli B; Cafaro A; Maboko L; Hoelscher M; Gavioli R; Saathoff E; Geldmacher C
BMC Infect Dis; 2016 Jul; 16():344. PubMed ID: 27450538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
